2022
Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.
Morschhauser F, Jiang Y, Jardin F, Herrera A, Sehn L, Herbaux C, Flowers C, Phillips T, Guillermo A, Diefenbach C, Gregory G, Kim A, Barbui A, Balasubramanian S, Harris W, Hirata J, Paulson J, Lee C, Lenz G. Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial. Journal Of Clinical Oncology 2022, 40: 7517-7517. DOI: 10.1200/jco.2022.40.16_suppl.7517.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPola-R-CHPProgression-free survivalR-CHOPPrognostic impactMultivariate analysisBCL6-RUntreated diffuse large B-cell lymphomaProgression-free survival eventsProgression-free survival estimatesLarge B-cell lymphomaMultivariate Cox regression modelDouble expressor lymphomaSubgroups of ptsTranslocation of MYCTriple-hit lymphomaAssociated with poor outcomesB-cell lymphomaMYC protein expressionResults of univariate analysisCox regression modelsBCL2+Cell of originOverexpression of BCL2Fluorescence in situ hybridizationTRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma
Harris W, Bataillard E, Choi Y, El-Galaly T, Cuchelkar V, Henneges C, Kwan A, Schneider D, Paulson J, Nielsen T. TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. JCO Clinical Cancer Informatics 2022, 6: e2100121. PMID: 35044836, DOI: 10.1200/cci.21.00121.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaR-CHOPFirst-line treatment of diffuse large B-cell lymphomaDiagnosed DLBCLTreatment of diffuse large B-cell lymphomaCourses of R-CHOPPresence of cardiovascular diseaseFirst-line treatmentProportion of patientsArea under the curveRoutine clinical settingCharlson Comorbidity IndexStandard of careHigh-risk categoryStandard chemoimmunotherapyChemotherapy toxicityCreatinine clearanceInferior outcomesBaseline characteristicsLogistic regression modelsComorbidity indexPatient frailtyEnd points
2020
Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients
Jemaa S, Tracy S, Bottos A, de Crespigny A, Bengtsson T, Nielsen T, Paulson J. Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients. Blood 2020, 136: 8-9. DOI: 10.1182/blood-2020-134780.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDiffuse large B-cell lymphoma patientsCurrent equity holderInternational Prognostic IndexTotal metabolic tumor volumeFluorodeoxyglucose-positron emission tomographyF Hoffmann-La RocheArea under the receiver operating characteristic curveR-CHOPPrognostic valueClinical featuresFluorodeoxyglucose-positron emission tomography imagingBCL2 expressionAssociated with reduced PFSInternational Prognostic Index categoryPrognostic value of Bcl2F. Hoffmann-La RocheB-cell lymphoma patientsLarge B-cell lymphomaCell of origin (COOMultivariable Cox-pH modelsPrognostic modelUnivariate Cox proportional hazardsBaseline imaging featuresMetabolic tumor volumeTRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making
Bataillard E, Harris W, El-Galaly T, Kwan A, Henneges C, Paulson J, Nielsen T. TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making. Blood 2020, 136: 34-35. DOI: 10.1182/blood-2020-134904.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCurrent equity holderArea under the receiver operating characteristic curveAverage relative dose intensityCharlson Comorbidity IndexBone marrow lymphocytesR-CHOPAnti-CD20Progressive diseaseWithdrawal of cyclophosphamideAdverse eventsMarrow lymphocytesDiffuse large B-cell lymphoma patientsLong-term event free survivalTreatment of diffuse large B-cell lymphomaClinical trialsDose intensity of cyclophosphamideProportion of Th cellsTreated with R-CHOPF. Hoffmann-La RocheHigh risk of relapseLarge B-cell lymphomaAlternative therapiesR-CHOP treatmentRelative dose intensityThe Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington S, Vercellino L, Zaucha J, Carvalho I, da Silva Maria G, Decazes P, Viailly P, Tilly H, Berriolo-Riedinger A, Casasnovas R, Hüttmann A, Ilyas H, Mikhaeel G, Dunn J, Cottereau A, Schmitz C, Paulson J, Nielsen T, Meignan M. The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136544.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaLarge B-cell lymphomaMetabolic tumor volumeProgression-free survivalB-cell lymphomaClinical trialsR-CHOPOverall survivalTumor volumeNewly diagnosed diffuse large B-cell lymphomaTotal metabolic tumor volumeStandard of careECOG PSCurative intentImmuno-chemotherapyPatientsMultiple centersEarly identificationCohortLymphomaTrialsSurvivalMultiple cohortsBaselineTMTV